^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSI-H/dMMR + KMT2D mutation

    i
    Other names: MSI-H, Microsatellite instability - high, dMMR, KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10
    Entrez ID:
    8085
    Related biomarkers:
    Expression
    Mutation
    Others
    over1year
    Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study. (ASCO-GI 2023)
    Pucotenlimab demonstrated durable antitumor activity and manageable safety for previously treated patients with advanced MSI-H/dMMR solid tumors. KMT2D gene mutation, along with NLR and TMB, warrants further investigation as predictive biomarkers. Clinical trial information: NCT03704246.
    Clinical • P2 data • Mismatch repair • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • KMT2D (Lysine Methyltransferase 2D)
    |
    PD-L1 expression • MSI-H/dMMR • KMT2D mutation • MSI-H/dMMR + KMT2D mutation
    |
    Puyouheng (pucotenlimab)